SLCO1B1, solute carrier organic anion transporter family member 1B1, is also known as solute carrier family 21 member 6 (SLC21A6). It is encoded by the SLCO1B1 gene in humans and belongs to SLC21A family of solute carriers. This gene is conserved in chimpanzee, chicken, rhesus monkey and frog. 17 organisms have been reported to contain orthologs with this gene. SLCO1B1 is restricted expressed in the liver and is involved in sodium-independent uptake of organic anions.
|Basic Information of SLCO1B1|
|Protein Name||Solute carrier organic anion transporter family member 1B1|
|Aliases||LST1, OATP1B1, OATP2, OATPC, SLC21A6|
|Organism||Homo sapiens (Human)|
SLCO1B1 gene encodes a sodium-independent transporter - SLCO1B1, which mediates cellular uptake of organic anions in the liver specifically. This transmembrane transporter is involved in the sodium-independent uptake of numerous endogenous compounds, such as leukotriene C4, 17-beta-glucuronosyl estradiol and bilirubin. In addition, SLCO1B1 is also involved in the removal of drug compounds including bromosulfophthalein, statins, and rifampin from the blood into the hepatocytes. If the gene encoding this protein has polymorphisms, the transporter function will be impaired. SLCO1B1 deficiency can affect methotrexate toxicity possibly through endogenous metabolites mediated communication between OAT1/OAT3 and SLCO1B1. SLCO1B1 can be used as a potential in vivo biomarker for transporter mediated drug-drug interactions. SLCO1B1 variants are associated with therapeutic response to thiazolidinediones in patients with Type 2 diabetes.
Fig.1 Model of the transmembrane pore of OATP1B1 and OATP1B3. (Gruetz, 2016)
This article indicates that SLCO1B1 deficiency can affect methotrexate toxicity possibly through endogenous metabolites mediated communication between OAT1/OAT3 and SLCO1B1.
This article demonstrates that SLCO1B1 (T521C) is susceptible to liver damage in humans when exposed to AFB1 and/or MC-LR in rural areas of China.
This article indicates that SLCO1B1 rs4149056 genotype is not related to the risk of statin-associated muscle symptoms in patients with familial hypercholesterolemia.
This article shows that SLCO1B1 can be used to represent potential in vivo biomarker for transporter mediated drug-drug interactions.
This article shows that SLCO1B1 variants are associated with therapeutic response to thiazolidinediones in patients with Type 2 diabetes.
To provide superior membrane protein preparation services, we have established versatile Magic™ membrane protein production platform to facilitate the projects of numerous worldwide customers. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLCO1B1 antibody development services.
Creative Biolabs is dedicated to helping our customers for facilitating their research using our well-established platform. With professional scientists and skillful technologies, we are glad to provide membrane protein services but not limited to those. For more detailed information, please feel free to contact us.